These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31068457)

  • 1. Reprogramming of Isocitrate Dehydrogenases Expression and Activity by the Androgen Receptor in Prostate Cancer.
    Gonthier K; Poluri RTK; Weidmann C; Tadros M; Audet-Walsh É
    Mol Cancer Res; 2019 Aug; 17(8):1699-1709. PubMed ID: 31068457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer.
    Gonthier K; Weidmann C; Berthiaume L; Jobin C; Lacouture A; Lafront C; Harvey M; Neveu B; Loehr J; Bergeron A; Fradet Y; Lacombe L; Riopel J; Latulippe É; Atallah C; Shum M; Lambert JP; Pouliot F; Pelletier M; Audet-Walsh É
    Mol Oncol; 2023 Oct; 17(10):2109-2125. PubMed ID: 37086156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer.
    Audet-Walsh É; Vernier M; Yee T; Laflamme C; Li S; Chen Y; Giguère V
    Mol Cancer Res; 2018 Sep; 16(9):1396-1405. PubMed ID: 29784665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic consequences of oncogenic IDH mutations.
    Parker SJ; Metallo CM
    Pharmacol Ther; 2015 Aug; 152():54-62. PubMed ID: 25956465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
    Chang S; Yim S; Park H
    Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH1R132H Promotes Malignant Transformation of Benign Prostatic Epithelium by Dysregulating MicroRNAs: Involvement of IGF1R-AKT/STAT3 Signaling Pathway.
    Zhang L; Qi M; Feng T; Hu J; Wang L; Li X; Gao W; Liu H; Jiao M; Wu Z; Bai X; Bie Y; Liu L; Han B
    Neoplasia; 2018 Feb; 20(2):207-217. PubMed ID: 29331887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases.
    Minemura H; Takagi K; Sato A; Yamaguchi M; Hayashi C; Miki Y; Harada-Shoji N; Miyashita M; Sasano H; Suzuki T
    Breast Cancer; 2021 Jul; 28(4):915-926. PubMed ID: 33713004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen.
    Whitworth H; Bhadel S; Ivey M; Conaway M; Spencer A; Hernan R; Holemon H; Gioeli D
    PLoS One; 2012; 7(6):e38950. PubMed ID: 22761715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative analysis of AR-mediated transcriptional regulatory network reveals IRF1 as an inhibitor of prostate cancer progression.
    Cheng Y; Wang D; Jiang J; Huang W; Li D; Luo J; Gu W; Mo W; Wang C; Li Y; Gu S; Xu Y
    Prostate; 2020 May; 80(8):640-652. PubMed ID: 32282098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
    Sharma H
    Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDH mutations in cancer and progress toward development of targeted therapeutics.
    Dang L; Yen K; Attar EC
    Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
    Deng X; Shao G; Zhang HT; Li C; Zhang D; Cheng L; Elzey BD; Pili R; Ratliff TL; Huang J; Hu CD
    Oncogene; 2017 Mar; 36(9):1223-1231. PubMed ID: 27546619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor reverses the oncometabolite R-2-hydroxyglutarate-induced prostate cancer cell invasion via suppressing the circRNA-51217/miRNA-646/TGFβ1/p-Smad2/3 signaling.
    Xu H; Sun Y; You B; Huang CP; Ye D; Chang C
    Cancer Lett; 2020 Mar; 472():151-164. PubMed ID: 31846689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.
    Tan PY; Chang CW; Chng KR; Wansa KD; Sung WK; Cheung E
    Mol Cell Biol; 2012 Jan; 32(2):399-414. PubMed ID: 22083957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity.
    Link KA; Balasubramaniam S; Sharma A; Comstock CE; Godoy-Tundidor S; Powers N; Cao KH; Haelens A; Claessens F; Revelo MP; Knudsen KE
    Cancer Res; 2008 Jun; 68(12):4551-8. PubMed ID: 18559499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
    Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
    J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
    Upadhyay VA; Brunner AM; Fathi AT
    Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells.
    Levina E; Ji H; Chen M; Baig M; Oliver D; Ohouo P; Lim CU; Schools G; Carmack S; Ding Y; Broude EV; Roninson IB; Buttyan R; Shtutman M
    Oncotarget; 2015 May; 6(15):13088-104. PubMed ID: 26036626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction.
    Gondim DD; Gener MA; Curless KL; Cohen-Gadol AA; Hattab EM; Cheng L
    Appl Immunohistochem Mol Morphol; 2019; 27(10):722-725. PubMed ID: 30358614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.